Pablo A. Gaspar
YOU?
Author Swipe
View article: Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS Open
AIM: To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR-P): the Structured Interview for Psychosis-risk Syndromes (SIPS) and the Comprehensive Assessment of A…
View article: Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program Open
This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and biomarkers …
View article: Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Open
View article: The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures Open
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medica…
View article: Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Open
View article: Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open
View article: The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program Open
View article: Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program Open
This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables a…
View article: Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative Open
View article: Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative Open
Speech-based detection of early psychosis is progressing at a rapid pace. Within this evolving field, the Accelerating Medicines Partnership® in Schizophrenia (AMP® SCZ) is uniquely positioned to deepen our understanding of how language an…
View article: The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures Open
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medica…
View article: Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Open
View article: Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Open
Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascert…
View article: The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program Open
Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying p…
View article: Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairmen…
View article: Clinical prediction model for transition to psychosis in individuals meeting At Risk Mental State criteria
Clinical prediction model for transition to psychosis in individuals meeting At Risk Mental State criteria Open
Background The At Risk Mental State (ARMS) (also known as the Ultra or Clinical High Risk) criteria identify individuals at high risk for psychotic disorder. However, there is a need to improve prediction as only about 18% of individuals m…
View article: Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical …
View article: Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and …
View article: Imitative inhibitory control is associated with psychotic experiences in a sample from the general population
Imitative inhibitory control is associated with psychotic experiences in a sample from the general population Open
Psychotic experiences (PE) are prevalent and associated with several negative mental health outcomes in both clinical and general population, particularly in young people. A promising avenue to understand the mechanisms underlying PE is to…
View article: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis Open
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories a…
View article: 8102 Hyperandrogenism and its Influence on Emotional and Social Development in Adolescent Daughters of Women with Polycystic Ovary Syndrome
8102 Hyperandrogenism and its Influence on Emotional and Social Development in Adolescent Daughters of Women with Polycystic Ovary Syndrome Open
Disclosure: J.P. del Rio: None. R. Gonzalo: None. M. Maliqueo: None. B. Echiburu: None. A. Ladron de Guevara: None. P. Gaspar: None. M. Alejandro: None. N.R. Crisosto: None. Introduction: Polycystic Ovarian Syndrome (PCOS) is the most prev…
View article: 8102 Hyperandrogenism and its Influence on Emotional and Social Development in Adolescent Daughters of Women with Polycystic Ovary Syndrome
8102 Hyperandrogenism and its Influence on Emotional and Social Development in Adolescent Daughters of Women with Polycystic Ovary Syndrome Open
Disclosure: J.P. del Rio: None. R. Gonzalo: None. M. Maliqueo: None. B. Echiburu: None. A. Ladron de Guevara: None. P. Gaspar: None. M. Alejandro: None. N.R. Crisosto: None. Introduction: Polycystic Ovarian Syndrome (PCOS) is the most prev…
View article: Fixational eye movements and their associated evoked potentials during natural vision are altered in schizophrenia
Fixational eye movements and their associated evoked potentials during natural vision are altered in schizophrenia Open
View article: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis Open
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories a…
View article: Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive impairment in early stages of psychosis
Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive impairment in early stages of psychosis Open
The MoCA describes lower scores in cognition across early stages of psychosis and may be a useful low-cost assessment instrument in early intervention centers of poorly resourced settings.
View article: Disrupted third visual pathway function in schizophrenia: Evidence from real and implied motion processing
Disrupted third visual pathway function in schizophrenia: Evidence from real and implied motion processing Open
View article: RELATION BETWEEN COGNITIVE IMPAIRMENTS IN ALZHEIMER DISEASE AND DEPRESSION
RELATION BETWEEN COGNITIVE IMPAIRMENTS IN ALZHEIMER DISEASE AND DEPRESSION Open
View article: Development of the <scp>PSYCHS</scp> : Positive SYmptoms and Diagnostic Criteria for the <scp>CAARMS</scp> Harmonized with the <scp>SIPS</scp>
Development of the <span>PSYCHS</span> : Positive SYmptoms and Diagnostic Criteria for the <span>CAARMS</span> Harmonized with the <span>SIPS</span> Open
Aim To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR‐P): the Structured Interview for Psychosis‐risk Syndromes (SIPS) and the Comprehensive Assessment of At…
View article: Bottom-up and top-down contributions to impaired motion processing in schizophrenia
Bottom-up and top-down contributions to impaired motion processing in schizophrenia Open
Background and Hypothesis Motion processing deficits in schizophrenia have been linked to impairments in higher-order social-cognitive processes. The neural underpinnings are not fully understood but it has been hypothesized that middle te…
View article: Las anomalías precoces de la continuidad en el discurso constituyen biomarcadores predictivos de psicosis
Las anomalías precoces de la continuidad en el discurso constituyen biomarcadores predictivos de psicosis Open
Language is being systematized as an area of clinical research because it contains features that function as a biomarker for the prediction of psychosis. The aim of the study was to contrast two types of continuity features such as connect…